Drug Shortage Report for ERWINASE

Last updated on 2018-03-07 History
Report ID 2952
Drug Identification Number 02237815
Brand name ERWINASE
Common or Proper name Erwinia L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS
Market Status CANCELLED POST MARKET
Active Ingredient(s) ASPARAGINASE
Strength(s) 10000UNIT
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials
ATC code L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2017-03-14
Actual start date
Estimated end date 2017-06-30
Actual end date 2017-06-30
Shortage status Resolved
Updated date 2018-03-07
Company comments Reason for ongoing shortage in Canada (less than 3-months supply) due to global capacity constraints in manufacturing leading to just-in time supply with intermittent shortages. Additionally demand has increased from average of 51 packs per month to 105 packs per month.
Health Canada comments
Tier 3 Status No
Contact Address 84 QUAI CHARLES DE GAULLE CITY ONE
LYON, AUVERGNE-RHONE-ALPES
FRANCE 69006
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2017-03-15 English Compare
v2 2017-03-15 French Compare
v3 2017-03-16 English Compare
v4 2017-03-16 English Compare
v5 2017-03-16 French Compare
v6 2017-04-24 English Compare
v7 2017-04-24 French Compare
v8 2018-03-07 English Compare

Showing 1 to 8 of 8